Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
This is a study to determine if oral arginine will increase nitric oxide in sickle cell
disease (SCD) patients with acute chest syndrome (ACS). It will also assess the effects of
arginine in the body and how the body uses nitric oxide in ACS.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital & Research Center Oakland UCSF Benioff Children's Hospital Oakland